Compare UCTT & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | PBLS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2004 | 2026 |
| Metric | UCTT | PBLS |
|---|---|---|
| Price | $45.98 | $28.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $106.00 | $41.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $1,734,500,000.00 | N/A |
| Revenue This Year | $35.00 | N/A |
| Revenue Next Year | $39.86 | $288.07 |
| P/E Ratio | $73.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.49 | $22.66 |
| 52 Week High | $144.22 | $42.49 |
| Indicator | UCTT | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 48.47 |
| Support Level | $43.96 | $26.42 |
| Resistance Level | $58.39 | $28.48 |
| Average True Range (ATR) | 4.18 | 2.08 |
| MACD | 0.91 | 0.32 |
| Stochastic Oscillator | 42.04 | 53.86 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.